Nanotechnology Now - Press Release: "Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials: Nano-bio material kills cancer cells, leaves healthy cells unharmed"

Home > Press > Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials: Nano-bio material kills cancer cells, leaves healthy cells unharmed

Argonne scientist Elena Rozhkova examines brain cancer cells under a microscope. Rozhkova, along with researchers from the University of Chicago, has developed a way to attach a antibody to nanomaterial titanium dioxide and kill brain cancer cells.

Argonne scientist Elena Rozhkova examines brain cancer cells under a microscope. Rozhkova, along with researchers from the University of Chicago, has developed a way to attach a antibody to nanomaterial titanium dioxide and kill brain cancer cells.

Abstract:
Scientists from the U.S. Department of Energy's (DOE) Argonne National Laboratory and the University of Chicago's Brain Tumor Center have developed a way to target brain cancer cells using inorganic titanium dioxide nanoparticles bonded to soft biological material.

Argonne, University of Chicago scientists develop targeted cancer treatment using nanomaterials: Nano-bio material kills cancer cells, leaves healthy cells unharmed

Argonne, IL | Posted on August 21st, 2009

Thousands of people die from malignant brain tumors every year, and the tumors are resistant to conventional therapies. This nano-bio technology may eventually provide an alternative form of therapy that targets only cancer cells and does not affect normal living tissue.

"It is a real example of how nano and biological interfacing can be used for biomedical application," said scientist Elena Rozhkova with Argonne's Center for Nanoscale Materials. "We chose brain cancer because of its difficulty in treatment and its unique receptors."

This new therapy relies on a two-pronged approach. Titanium dioxide is a versatile photoreactive nanomaterial that can be bonded with biomolecules. When linked to an antibody, nanoparticles recognize and bind specifically to cancer cells. Focused visible light is shined onto the affected region, and the localized titanium dioxide reacts to the light by creating free oxygen radicals that interact with the mitochondria in the cancer cells. Mitochondria act as cellular energy plants, and when free radicals interfere with their biochemical pathways, mitochondria receive a signal to start cell death.

"The significance of this work lies in our ability to effectively target nanoparticles to specific cell surface receptors expressed on brain cancer cells," said Dr. Maciej S. Lesniak, Director of Neurosurgical Oncology at the University of Chicago Brain Tumor Center. "In so doing, we have overcome a major limitation involving the application of nanoparticles in medicine; namely, the potential of these agents to distribute throughout the body. We are now in a position to develop this exciting technology in preclinical models of brain tumors, with the

X-ray fluorescence microscopy done at Argonne's Advanced Photon Source also showed that the tumors' invadopodia, actin-rich micron scale protrusions that allow the cancer to invade surrounding healthy cells, can be also attacked by the titanium dioxide.

So far, tests have been done only on cells in a laboratory setting, but animal testing is planned for the next phase. Results show an almost 100 percent cancer cell toxicity rate after six hours of illumination and 80 percent after 48 hours following 5 minutes' exposure to focused light.

Also, since the antibody only targets the cancer cells, surrounding healthy cells are not affected—unlike other cancer treatments such as chemotherapy and radiotherapy.

Rozhkova said that a proof of concept is demonstrated; other cancers could be treated as well, using different targeting molecules, but research is in the early stages.

This work is published in a Nano Letters and is available online at http://pubs.acs.org/doi/full/10.1021/nl901610f.

Funding for this research was through the Department of Energy's Office of Basic Energy Sciences, National Cancer Institute, National Institute of Neurological Disorders and Stroke, Alliance for Cancer Gene Therapy, American Cancer Society and Brain Research Foundation.

The Center for Nanoscale Materials at Argonne is one of the five DOE Nanoscale Science Research Centers (NSRCs), premier national user facilities for interdisciplinary research at the nanoscale. Together the NSRCs comprise a suite of complementary facilities that provide researchers with state-of-the-art capabilities to fabricate, process, characterize and model nanoscale materials, and constitute the largest infrastructure investment of the National Nanotechnology Initiative. The NSRCs are located at DOE's Argonne, Brookhaven, Lawrence Berkeley, Oak Ridge and Sandia and Los Alamos National Laboratories. For more information about the DOE NSRCs, please visit nano.energy.gov.

####

About Argonne National Laboratory
Argonne National Laboratory seeks solutions to pressing national problems in science and technology. The nation's first national laboratory, Argonne conducts leading-edge basic and applied scientific research in virtually every scientific discipline. Argonne researchers work closely with researchers from hundreds of companies, universities, and federal, state and municipal agencies to help them solve their specific problems, advance America 's scientific leadership and prepare the nation for a better future. With employees from more than 60 nations, Argonne is managed by UChicago Argonne, LLC for the U.S. Department of Energy's Office of Science.

For more information, please click here

Contacts:
Brock Cooper
630/252-5565

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: